Page last updated: 2024-08-21

alpha-aminopyridine and Hyperglycemia, Postprandial

alpha-aminopyridine has been researched along with Hyperglycemia, Postprandial in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Chen, L; Fu, J; Fu, Q; Hu, Y; Huang, K; Tao, X; Xu, R; Yang, X	1
Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P	1
Agafonova, N; Cruz, M; Dodds, M; Katz, L; Kaur, P; Kewalramani, R; Manamley, N; Mudaliar, S; Pellacani, A; Raskin, P; Sierra-Johnson, J; Snyder, WJ	1
Castellano, D; Chakravartty, A; Chi, KN; Csonka, D; de Bono, J; Dirix, L; Fizazi, K; Gravis, G; Machiels, JP; Maier, J; Massard, C; Mellado, B; Mita, A; Turri, S	1
Sugimoto, Y; Yamada, J; Yoshikawa, T	1

Trials

3 trial(s) available for alpha-aminopyridine and Hyperglycemia, Postprandial

Article	Year
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:7 Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate	2017
AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:2 Topics: Adult; Aminopyridines; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drugs, Investigational; Enzyme Activators; Follow-Up Studies; Glucokinase; Glycated Hemoglobin; Headache; Humans; Hyperglycemia; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Least-Squares Analysis; Postprandial Period; Thiadiazoles; Triglycerides	2016
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asthenia; Chills; Diarrhea; Fever; Humans; Hyperglycemia; Imidazoles; Kallikreins; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Stomatitis; Vomiting	2017

Other Studies

2 other study(ies) available for alpha-aminopyridine and Hyperglycemia, Postprandial

Article	Year
Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering. Diabetes, 2022, 08-01, Volume: 71, Issue:8 Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diabetes Mellitus, Type 2; Glucose; Heart Diseases; Humans; Hyperglycemia; Insulins; Mice; MicroRNAs; Phosphodiesterase 4 Inhibitors	2022
p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. European journal of pharmacology, 1998, Oct-23, Volume: 359, Issue:2-3 Topics: 4-Aminobenzoic Acid; Adrenal Medulla; Adrenalectomy; Aminopyridines; Animals; Blood Glucose; Dose-Response Relationship, Drug; Ergolines; Fenclonine; Hyperglycemia; Indoles; Ketanserin; Male; Methysergide; p-Chloroamphetamine; para-Aminobenzoates; Piperazines; Propranolol; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Ritanserin; Serotonin; Serotonin Agents; Serotonin Antagonists; Tropisetron	1998

Article

Year

Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.

Diabetes, 2022, 08-01, Volume: 71, Issue:8

Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diabetes Mellitus, Type 2; Glucose; Heart Diseases; Humans; Hyperglycemia; Insulins; Mice; MicroRNAs; Phosphodiesterase 4 Inhibitors

2022

p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors.

European journal of pharmacology, 1998, Oct-23, Volume: 359, Issue:2-3

Topics: 4-Aminobenzoic Acid; Adrenal Medulla; Adrenalectomy; Aminopyridines; Animals; Blood Glucose; Dose-Response Relationship, Drug; Ergolines; Fenclonine; Hyperglycemia; Indoles; Ketanserin; Male; Methysergide; p-Chloroamphetamine; para-Aminobenzoates; Piperazines; Propranolol; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Ritanserin; Serotonin; Serotonin Agents; Serotonin Antagonists; Tropisetron

1998